1 eagent, N-[(2-pyridyldithio)-ethyl], 4-azido salicylamide.

2 an N-Mannich linkage between doxorubicin and salicylamide.

3 oxen, Nimesulide, Phenylbutazone, Piroxicam, Salicylamide, and Tolmetin.

4 ldehyde conjugate via an N-Mannich base of a salicylamide derivative.

5 ur continued efforts to optimize a series of salicylamide derivatives as potent inhibitors of HAdV in

6  A variety of gentisic acid, tetralin, and m-salicylamide derivatives were synthesized to test the po

7                                          The salicylamide-grafted PEI showed to be a reliable carrier

8 nd between that OH and the carbonyl O of the salicylamide linkage are important.

9 sted that the phenolic hydroxyl group in the salicylamide ring was required for activity, while the t

10                                              Salicylamide (SAL), an analgesic drug, caused a potent a

11 roup that spanned from the 5-position of the salicylamide to the 3'-position of cyanonilutamide.

12 by correlating the carbonyl carbon shifts of salicylamides to the regioselectivity of the associated

13                                          The salicylamide triggering molecule, previously developed t

14                                          The salicylamide was selected to serve as a trigger release

15                      A series of azole-fused salicylamides were prepared as analogues of antimycin an